4.7 Review

Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity

期刊

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 59, 期 12, 页码 7161-7169

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02009-15

关键词

-

资金

  1. NIH [GM103427, AI116723]
  2. Rheumatology Research Foundation Scientist Development Award
  3. Nebraska Research Initiative

向作者/读者索取更多资源

Toxoplasma gondii is an apicomplexan parasite of humans and other mammals, including livestock and companion animals. While chemotherapeutic regimens, including pyrimethamine and sulfadiazine regimens, ameliorate acute or recrudescent disease such as toxoplasmic encephalitis or ocular toxoplasmosis, these drugs are often toxic to the host. Moreover, no approved options are available to treat infected women who are pregnant. Lastly, no drug regimen has shown the ability to eradicate the chronic stage of infection, which is characterized by chemoresistant intracellular cysts that persist for the life of the host. In an effort to promote additional chemotherapeutic options, we now evaluate clinically available drugs that have shown efficacy in disease models but which lack clinical case reports. Ideally, less-toxic treatments for the acute disease can be identified and developed, with an additional goal of cyst clearance from human and animal hosts.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据